IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

被引：7
|
作者：
Huang, Chengliang [1 ,2 ]
Gan, Gregory N. [3 ,4 ]
Zhang, Jun [2 ,4 ]
机构：
[1] Southwest Med Univ, Affiliated Hosp, Dept Resp & Crit Care Med 2, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China
[2] Univ Kansas, Dept Internal Med, Div Med Oncol, Canc Ctr,Med Ctr, 3005 Wahl Hall East,3901 Rainbow Blvd, Kansas City, KS 66160 USA
[3] Univ Kansas, Dept Radiat Oncol, Canc Ctr, Med Ctr, 3005 Wahl Hall East,3901 Rainbow Blvd, Kansas City, KS 66160 USA
[4] Univ Kansas, Med Ctr, Canc Ctr, Dept Canc Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2020年 / 13卷 / 01期
关键词：
Extensive-stage small cell lung cancer; Immunotherapy; PD-1; PD-L1; Radiation therapy; CTLA-4; CD80; CD28; TIGIT; CD155 (PVR); EXPRESSION; PD-L1;
D O I：
10.1186/s13045-020-00898-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2-3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
    Chengliang Huang
    Gregory N. Gan
    Jun Zhang
    Journal of Hematology & Oncology, 13
  • [2] Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
    Zhang, Shuang
    Li, Shuang
    Cui, Yanan
    Zhao, Peiyan
    Sun, Xiaodan
    Cheng, Ying
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Immunotherapy in Extensive-Stage Small Cell Lung Cancer
    El Sayed, Rola
    Blais, Normand
    CURRENT ONCOLOGY, 2021, 28 (05) : 4093 - 4108
  • [4] Impact of cachexia on the efficacy of first-line immunotherapy in extensive-stage small-cell lung cancer patients.
    Fan, Xinyu
    Li, Butuo
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] The Value of Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy
    Wang, Y.
    Zeng, Y.
    Su, X.
    Jia, J.
    Zhou, T.
    Lu, Y.
    Zhao, L.
    Yang, Z.
    Fu, X.
    Cai, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E78 - E79
  • [6] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
    Horn, L.
    Mansfield, A. S.
    Szczesna, A.
    Havel, L.
    Krzakowski, M.
    Hochmair, M. J.
    Huemer, F.
    Losonczy, G.
    Johnson, M. L.
    Nishio, M.
    Reck, M.
    Mok, T.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Ding, B.
    Lopez-Chavez, A.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
  • [7] Efficacy and Safety of First-line Immunotherapy Plus Chemotherapy in Treating Elderly Patients With Extensive-stage Small Cell Lung Cancer
    Sonoda, M.
    Shinno, Y.
    Tamura, K.
    Yamaguchi, Y.
    Miyakoshi, J.
    Tateishi, A.
    Ikawa, Y.
    Torasawa, M.
    Shirasawa, M.
    Yoshida, T.
    Okuma, Y.
    Goto, Y.
    Horinouchi, H.
    Yamamoto, N.
    Ohe, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [8] IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
    Liu, S. V.
    Horn, L.
    Mok, T.
    Mansfield, A.
    De Boer, R.
    Losonczy, G.
    Sugawara, S.
    Dziadziuszko, R.
    Krzakowski, M.
    Smolin, A.
    Hochmair, M. J.
    Garassino, M. C.
    Lam, S.
    McCleland, M.
    Cardona, A.
    Morris, S.
    Reck, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1032 - S1033
  • [9] Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options
    Zugazagoitia, Jon
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 671 - +
  • [10] Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer
    Konala, Venu Madhav
    Madhira, Bhaskar Reddy
    Ashraf, Sara
    Graziano, Stephen
    ONCOLOGY, 2020, 98 (11) : 749 - 754
12345